"Wegovy: Medicare Expands Coverage for Heart-Related Benefits"
TL;DR
Novo Nordisk and Eli Lilly are inching closer to justifying their high valuations as the U.S. government announces plans to cover weight loss drug Wegovy for Medicare patients, potentially including other drugs like Zepbound for cardiovascular disease. This move could make the pharma giants' valuations seem less far-fetched, especially as obesity treatments become bigger sellers with Medicare's support.
Topics:healthhealthcarepharmaceuticals#eli-lilly#healthcarepharmaceuticals#medicare#novo-nordisk#obesity-drugs#valuation
- Breakingviews - Obesity drugs inch closer to outsize expectations Reuters
- Medicare Part D plans can cover Wegovy for cardiovascular patients The Washington Post
- Medicare plans can now cover the weight-loss drug Wegovy NPR
- Wegovy gains Medicare, Medicaid coverage for heart benefits Yahoo Finance
- Medicare allows coverage of Wegovy for heart patients MarketWatch
Want the full story? Read the original reporting
Read on Reuters